BACKGROUND: The genetic background of patients with hypertrophic cardiomyopathy (HCM) treated with alcohol septal ablation (ASA) and its relationship to the outcomes are not known. We aimed to investigate whether the outcome of genotype positive (G+) patients differs from genotype negative (G-) patients treated with ASA. METHODS: We included 129 HCM patients (mean age 54±13 years) treated with ASA in a tertiary cardiovascular center and performed next generation sequencing (NGS) based genomic testing. All patients were followed-up three months after the procedure and yearly thereafter. RESULTS: A total of 30 (23%) HCM patients were G+ patients. At the 3-months follow-up, both groups of patients had similar left ventricular outflow tract PG (16.9±15.7 mmHg in G+ vs. 16.3±18.8 mmHg in G-, P=0.73) and symptoms (follow-up NYHA class 1.40±0.62 vs. 1.37±0.53, P=0.99, follow-up CCS class 0.23±0.52 vs. 0.36±0.65, P=0.36). The independent predictors of all-cause mortality were baseline interventricular septum (IVS) thickness (HR 1.12, 95% CI: 1.00-1.26, P=0.049) and age at the time of ASA (HR 1.11, 95% CI: 1.06-1.17, P<0.01). The adjusted all-cause mortality rate did not differ significantly between G+ and G- patients (P=0.52). The adjusted combined mortality event rate did not differ between both groups (P=0.78). CONCLUSIONS: Despite more severe phenotype in G+ HCM patients, ASA is an equally effective treatment for LVOTO in G+ patients as it is for treating LVOTO in G- patients. The long-term outcome after ASA is similar in G+ and G- patients.

Department of Biology and Medical Genetics 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Cardiology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Zobrazit více v PubMed

Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012;60:705-15. 10.1016/j.jacc.2012.02.068 PubMed DOI

Elliott PM, Anastasakis A, Borger M, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014;35:2733-79. 10.1093/eurheartj/ehu284 PubMed DOI

Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of cardiology foundation/American heart association task force on practice guidelines. Circulation 2011;124:e783-831. PubMed

Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: Results from the Euro-ASA registry. Eur Heart J 2016;37:1517-23. 10.1093/eurheartj/ehv693 PubMed DOI

Veselka J, Polaková E, Bonaventura J. Update on alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Kardiol Pol 2019;77:160-1. 10.5603/KP.2019.0019 PubMed DOI

Veselka J. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a review of the literature. Med Sci Monit 2007;13:RA62-8. PubMed

Veselka J, Zemánek D, Fiedler J, et al. Real-time myocardial contrast echocardiography for echo-guided alcohol septal ablation. Arch Med Sci 2009;5:271-2.

Veselka J, Lawrenz T, Stellbrink C, et al. Early outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A European multicenter and multinational study. Catheter Cardiovasc Interv 2014;84:101-7. 10.1002/ccd.25236 PubMed DOI

Bonaventura J, Norambuena P, Tomašov P, et al. The utility of the Mayo Score for predicting the yield of genetic testing in patients with hypertrophic cardiomyopathy. Arch Med Sci 2019;15:641-9. 10.5114/aoms.2018.78767 PubMed DOI PMC

Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24. 10.1038/gim.2015.30 PubMed DOI PMC

Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. Circulation 2018;138:1387-98. 10.1161/CIRCULATIONAHA.117.033200 PubMed DOI PMC

Lopes LR, Brito D, Belo A, et al. Genetic characterization and genotype-phenotype associations in a large cohort of patients with hypertrophic cardiomyopathy - An ancillary study of the Portuguese registry of hypertrophic cardiomyopathy. Int J Cardiol 2019;278:173-9. 10.1016/j.ijcard.2018.12.012 PubMed DOI

Bos JM, Will ML, Gersh BJ, et al. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2014;89:727-37. 10.1016/j.mayocp.2014.01.025 PubMed DOI PMC

Lopes LR, Syrris P, Guttmann OP, et al. Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart 2015;101:294-301. 10.1136/heartjnl-2014-306387 PubMed DOI PMC

Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: Septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 2006;81:459-67. 10.4065/81.4.459 PubMed DOI

Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008;83:630-8. 10.1016/S0025-6196(11)60890-2 PubMed DOI

Veselka J, Tomašov P, Januška J, et al. Obstruction after alcohol septal ablation is associated with cardiovascular mortality events. Heart 2016;102:1793-6. 10.1136/heartjnl-2016-309699 PubMed DOI

Fokstuen S, Munoz A, Melacini P, et al. Rapid detection of genetic variants in hypertrophic cardiomyopathy by custom DNA resequencing array in clinical practice. J Med Genet 2011;48:572-6. 10.1136/jmg.2010.083345 PubMed DOI

Meder B, Haas J, Keller A, et al. Targeted Next-Generation Sequencing for the Molecular Genetic Diagnostics of Cardiomyopathies. Circ Cardiovasc Genet 2011;4:110-22. 10.1161/CIRCGENETICS.110.958322 PubMed DOI

Murphy SL, Anderson JH, Kapplinger JD, et al. Evaluation of the Mayo Clinic Phenotype-Based Genotype Predictor Score in Patients with Clinically Diagnosed Hypertrophic Cardiomyopathy. J Cardiovasc Transl Res 2016;9:153-61. 10.1007/s12265-016-9681-5 PubMed DOI PMC

Walsh R, Thomson KL, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med 2017;19:192-203. 10.1038/gim.2016.90 PubMed DOI PMC

Ingles J, Goldstein J, Thaxton C, et al. Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circ Genom Precis Med 2019;12:e002460. 10.1161/CIRCGEN.119.002460 PubMed DOI PMC

Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: Expanded panels offer limited additional sensitivity. Genet Med 2015;17:880-8. 10.1038/gim.2014.205 PubMed DOI

Ko C, Arscott P, Concannon M, et al. Genetic testing impacts the utility of prospective familial screening in hypertrophic cardiomyopathy through identification of a nonfamilial subgroup. Genet Med 2018;20:69-75. 10.1038/gim.2017.79 PubMed DOI

Veselka J, Faber L, Jensen MK, et al. Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. Can J Cardiol 2018;34:16-22. 10.1016/j.cjca.2017.10.020 PubMed DOI

Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy

Genetic Testing in Patients with Hypertrophic Cardiomyopathy